Iradimed Stock Price, News & Analysis

iRadimed Corporation (NASDAQ: IRMD) is a medical device company focused on Magnetic Resonance Imaging (MRI) compatible medical devices. According to the company’s public disclosures, it designs, manufactures, markets, and distributes MRI-compatible medical devices, accessories, disposables, and related services. iRadimed’s products are used during MRI procedures and are intended to address safety and performance challenges created by the powerful magnetic fields and radio-frequency environment of MRI systems.

Core business and product focus

iRadimed states that it is the only known provider of a non-magnetic intravenous (IV) infusion pump system specifically designed for safe use during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio-frequency interference and can be dangerous to operate near an MRI magnet. To address these issues, the company developed its MRidium® MRI-compatible IV infusion pump system, which uses a non-magnetic ultrasonic motor, uniquely designed non‑ferrous parts, and other features intended to safely and predictably deliver anesthesia and other IV fluids during MRI scans.

The MRidium system is designed to provide accurate, safe, and dependable fluid delivery before, during, and after an MRI scan. iRadimed’s disclosures emphasize that this is particularly important for critically ill patients who cannot be removed from vital medications and for children and infants who generally must be sedated to remain immobile during MRI procedures.

MRI-compatible patient monitoring

In addition to infusion pumps, iRadimed offers the 3880 MRI-compatible patient vital signs monitoring system. This system is described as being designed with non-magnetic components and other special features so it can safely and accurately monitor a patient’s vital signs during MRI procedures. The company reports that the Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which allows it to operate virtually anywhere in the MRI scanner room.

The 3880 monitor has a compact, lightweight design that allows it to travel with the patient from the critical care unit to the MRI suite and back. According to iRadimed, this supports uninterrupted vital signs monitoring and reduces the time critically ill patients are away from critical care units. Features disclosed for the 3880 system include:

• Wireless ECG with dynamic gradient filtering
• Wireless SpO2 using Masimo® algorithms
• Non-magnetic respiratory CO₂
• Invasive and non-invasive blood pressure
• Patient temperature
• Optional advanced multi-gas anesthetic agent unit with continuous Minimum Alveolar Concentration measurements

iRadimed describes the 3880 monitor as having an easy-to-use design that enables effective communication of patient vital signs information to clinicians.

Next-generation MRI infusion technology

iRadimed has also announced the MRidium® 3870 IV Infusion Pump System, described as a next-generation, MRI-compatible infusion pump. The company reported that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the MRidium 3870. This device extends iRadimed’s position as a supplier of non-magnetic MRI infusion pump devices, a position the company states was established with its first-generation device in 2005.

According to iRadimed, the MRidium 3870 features:

• A non-magnetic ultrasonic pump motor
• Non-interfering RF emissions
• Non-ferrous components for operation in high-magnetic-field environments
• An enhanced, intuitive graphical touchscreen user interface
• Advanced safety features
• The ability to operate independently or be combined with additional 3870 pumps to form a four-channel IV infusion pump system for critical care patients
• A modern drug library solution that accommodates multiple patient care area drug listings

The company indicates that these enhancements are intended to address evolving needs in MRI environments by supporting patient safety and workflow efficiency during MRI scans.

Customer base and geographic reach

In its earlier description, iRadimed stated that its MRI products are sold to hospitals and acute care facilities in the United States and internationally. The company has also disclosed that a majority of its revenue is generated in the United States. Its filings and press releases emphasize domestic sales data and reference international distribution, indicating a presence in both U.S. and non-U.S. healthcare markets.

Industry classification and stock listing

iRadimed operates in the surgical and medical instrument manufacturing industry within the broader manufacturing sector. The company is incorporated in Delaware and its common stock trades on the NASDAQ Global Market under the symbol IRMD, as disclosed in its SEC filings. The company has also reported, in at least one filing, that its common stock was listed on the NASDAQ Capital Market, reflecting historical listing information.

Business model elements disclosed by the company

From its public releases, iRadimed’s business model centers on:

• Design and development of MRI-compatible medical devices for use in and around MRI scanners
• Manufacturing of non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems
• Sales of devices, including MRI-compatible IV infusion pump systems, MRI-compatible patient vital signs monitoring systems, and ferro magnetic detection systems
• Recurring revenue related to disposables, extended maintenance or warranty agreements, and services and other support associated with its installed base of devices

Revenue tables in the company’s financial press releases break out device revenue into MRI-compatible IV infusion pump systems, MRI-compatible patient vital signs monitoring systems, and ferro magnetic detection systems, along with separate lines for amortization of extended maintenance or warranty agreements, disposables, and services and other revenue.

Financial and operating characteristics (structural, not time-specific)

Across multiple quarters, iRadimed has reported record revenue and has highlighted a multi-quarter sequence of record results. The company has also disclosed high gross profit margins and significant domestic sales as a percentage of total revenue. While specific figures are time-bound and change from period to period, the repeated references to record revenue and strong margins illustrate that the business model is centered on higher-value MRI-compatible devices and associated consumables and services.

iRadimed has also discussed cash flow from operations and the use of non-GAAP financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, and free cash flow. In its explanations, the company states that these non-GAAP measures exclude stock-based compensation expense, certain operating expenses that it believes are not indicative of ongoing core operating performance, and infrequent income tax items. Free cash flow is defined as net cash provided by operating activities less certain investing cash flows related to internal software development and purchases of property and equipment.

Facilities and corporate governance

SEC filings indicate that iRadimed is headquartered in Florida, with references to locations in Winter Springs and Orlando. The company has disclosed the construction and completion of a new facility in Orlando, Florida, describing it as a new facility intended to support operations. Details in its financial press releases note construction costs and timing, indicating that the facility is intended to support manufacturing and operational needs.

Corporate governance disclosures in SEC filings and press releases describe a Board of Directors that includes independent directors and committee structures such as an Audit Committee and a Compensation Committee. The company has reported changes in board composition, including the retirement of a director and the appointment of a new independent director who serves on the Audit Committee and chairs the Compensation Committee. Stockholder voting results disclosed in a Form 8-K show election of directors, ratification of an independent registered public accounting firm, and approval of an advisory resolution on executive compensation.

Dividends and capital allocation

iRadimed has announced regular quarterly cash dividends on its common stock and, in one press release, a special cash dividend. The company’s Board of Directors has described a focus on maximizing returns to stockholders and has linked dividend decisions to factors such as financial condition, earnings, capital requirements, cash flows, liquidity needs, legal and regulatory requirements, general business conditions, growth opportunities, and other considerations. The company has also stated that there can be no assurance that future dividends will be declared, and that any future dividends remain at the discretion of the Board.

Recognition and market perception

In one press release, iRadimed reported that it was named to TIME’s list of America’s Growth Leaders for 2026, with the company ranked 79th on that list. The methodology described in that announcement notes that the ranking evaluated U.S.-based public companies on revenue growth, financial stability, and stock performance, with the highest-scoring companies earning the distinction.

Summary

Overall, iRadimed Corporation is described in its own disclosures as a company dedicated to MRI-compatible medical devices, with a particular emphasis on non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems. Its products are intended to function safely and reliably in the MRI environment and to support the care of critically ill and other patients undergoing MRI procedures. The company generates revenue from devices, related disposables, extended maintenance or warranty agreements, and services, and its common stock is listed on the NASDAQ under the symbol IRMD.